Comparison of the impact of annual and semiannual mass drug administration on lymphatic filariasis prevalence in Flores Island, Indonesia by Supali, Taniawati et al.




Comparison of the impact of annual and
semiannual mass drug administration on lymphatic











See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Supali, Taniawati; Djuardi, Yenny; Lomiga, Adriani; Linda, Sovie N.; Iskandar, Elisa; Goss, Charles W.; Miller, John P.; Weil, Gary J.;
and Fischer, Peter U., ,"Comparison of the impact of annual and semiannual mass drug administration on lymphatic filariasis
prevalence in Flores Island, Indonesia." The American Journal of Tropical Medicine and Hygiene.100,2. 336-343. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/7562
Authors
Taniawati Supali, Yenny Djuardi, Adriani Lomiga, Sovie N. Linda, Elisa Iskandar, Charles W. Goss, John P.
Miller, Gary J. Weil, and Peter U. Fischer
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/7562
Am. J. Trop. Med. Hyg., 100(2), 2019, pp. 336–343
doi:10.4269/ajtmh.18-0570
Copyright © 2019 by The American Society of Tropical Medicine and Hygiene
Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic
Filariasis Prevalence in Flores Island, Indonesia
Taniawati Supali,1 Yenny Djuardi,1 Adriani Lomiga,2 Sovie Nur Linda,1 Elisa Iskandar,1 Charles W. Goss,3 John Philip Miller,3
Gary J. Weil,4 and Peter U. Fischer4*
1Department of Parasitology, Faculty ofMedicine,Universitas Indonesia, Jakarta, Indonesia; 2ProgramStudi IlmuKesehatanMasyarakat, Program
Pascasarjana, Universitas Nusa Cendana, Kupang, Indonesia; 3Division of Biostatistics, Washington University School of Medicine, St. Louis,
Missouri; 4Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
Abstract. We compared the impact of annual and semiannual mass drug administration (MDA) on the prevalence of
Brugia timori and Wuchereria bancrofti in Flores Island. Two villages (Paga, B. timori only; Lewomada, co-endemic)
received annual MDAwith diethylcarbamazine/albendazole and a larger village (Pruda, co-endemic) received semiannual
MDA. Infection parameters (microfilariae [Mf], antibodies to recombinant filarial antigen BmR1 [Brugia Rapid (BR)], and a
test for W. bancrofti antigenemia [immunochromatographic test (ICT)]) were assessed before and after treatment. The
crudeMf prevalence in Prudadecreased after five semiannual treatments from14.2% to 1.2%,whereas theMf prevalence
in the other two villages decreased after three annual treatments from3.9% to 0%and from 5% to 0.3%, respectively. ICT
positivity prevalence in Pruda and Lewomada decreased from 22.9% and 6.5% to 7% and 0.8%, respectively, whereas
BR antibody prevalence in Pruda, Lewomada, and Paga decreased from 28.9%, 31.7%, and 12.5% to 3.6%, 4.1%, and
1.8%, respectively. Logistic regressionanalysis indicated that thatMf,BR, and ICTprevalencedecreasedsignificantly over
time and that for the Mf and ICT outcomes the semiannual treatment had higher odds of positivity. Model-adjusted
prevalence estimates revealed that apparent differences in treatment effectiveness were driven by differences in baseline
prevalence and that adjustedprevalencedeclinedmore rapidly in thesemiannual treatment group.Weconclude that in this
setting, annual MDA was sufficient to reduce Mf prevalence to less than 1% in areas with low to moderate baseline
prevalence. Semiannual MDA was useful for rapidly reducing Mf prevalence in an area with higher baseline endemicity.
INTRODUCTION
Lymphatic filariasis (LF) is a common neglected tropical
disease in Indonesia thatmayhinder economicdevelopment.1
The country committed to the Global Program to Eliminate
Lymphatic Filariasis (GPELF) in the year 2002, but progress
has been slow and variable. The national LF elimination pro-
gram is based on annual mass drug administration (MDA)
using a single dose of diethylcarbamazine (DEC) combined
with albendazole (ALB) in all areas with microfilaremia (Mf) or
antigen (Wuchereria bancrofti) prevalence of 1% or higher. In
2016, itwas estimated that a population of about 62million still
requiredMDA for LF elimination. Indonesia’s population at risk
ranks third in the world, behind only India and Nigeria.2
The epidemiology of LF in Indonesia is unique because it is
caused by three different filarial species, namelyW. bancrofti,
Brugia malayi, and Brugia timori. Furthermore, W. bancrofti
and B. malayi each have several distinct ecotypes with dif-
ferent vector species and ecology. This variability leads to
varied transmission dynamics and responses to intervention.3
Brugia timori is endemic in eastern Indonesia (east of the
Wallace line).Wuchereria bancrofti is sometimes co-endemic
with B. timori, but it is usually transmitted by sympatric but
different anopheline vector species. Previous studies by our
group have shown that annual MDA can be efficiently per-
formed in eastern Indonesia and provided evidence that
LF caused by B. timori and W. bancrofti can be locally
eliminated.4,5 Unfortunately, only 48 of the 235 evaluation
units in Indonesia have passed transmission assessment
surveys (TAS) and stopped MDA, whereas 80% of the
implementation units still require MDA.2 Therefore, cost-
effective strategies to accelerate LF elimination are highly
desirable.
Previous modeling studies based on data from Ghana and
India predicted that semiannual MDA would significantly
speed up LF elimination and reduce the overall cost of MDA
programs by 11–18%.6 To test this hypothesis for Indonesia,
we compared the impact of annual and semiannual MDA with
FIGURE 1. Map of Indonesia and Flores Island showing the study
sites in Sikka district. Pruda received semiannual mass drug admin-
istration (MDA), whereas Lewomada and Paga received annual MDA.
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DEC and ALB on filarial infection parameters in selected areas
of Flores Island where B. timori andW. bancrofti are endemic.
We found that both treatment regimens were effective for
dramatically reducing infection markers with no marked
advantage of twice-yearly MDA.
METHODS
Ethical approval and selection of the study area. The
study received ethical approval from the Ethics Committee of
Faculty of Medicine, University of Indonesia (No.61/PT02.FK/
ETIK/2011). This study was registered at ClinicalTrials.gov
with identifier No NCT01905423.
The study was initiated in 2011 with screening surveys to
identify and select LF-endemic villages in Sikka, Flores Timur,
and Lembata districts in the province East Nusa Tenggara
Timur. In these surveys Mf were detected by thick night blood
smears. In Flores Timur, a convenience sample of 2,584
subjects residing in 24 villages was tested and eight villages
wereMfpositivewith crudeprevalencebetween1%and16%.
One village was co-endemic for B. timori and W. bancrofti,
whereas all other villages were endemic forW. bancrofti only.
In Lembata, we screened 653 subjects from seven villages,
and only nine W. bancrofti Mf-positive individuals were iden-
tified in a single village. InSikkadistrict, 2,341 subjects from17
villages were tested for Mf, and 16 villages were positive for
B. timoriwith crudeMf prevalence of 1–22%. In addition, three
villages were co-endemic for W. bancrofti. Because we wan-
ted to focus on brugian filariasis, we selected three villages in
Sikka district for our study.
Study area and population. Sikka district (population ap-
proximately 300,000 in 2010) is located on Flores Island
(Figure 1). The district comprises 21 sub-districts with 147
villages that are served by 22 primary health centers (Pus-
kesmas). With the exception of the district capital Maumere,
most areas are rural and often served only by dirt roads or boat
(http://www.sikkakab.go.id). The study village Paga is in the
southwestern part of Sikka, whereas Pruda and Lewomada
are in the more remote eastern part of the district (Figure 1).
Four cross-sectional field surveys were performed in the
study villages, at baseline before MDA and at 12 months,
24 months, and 36 months after the initial MDA. During the
survey, all eligible individuals aged 5 years and older who
consented to the study provided demographic information
(gender, age, and bed net use) and were tested for Mf, anti-
filarial antibodies, and circulating filarial antigen. Individuals
who were not eligible for MDA or who moved to the village
within the last year were not included in the study. Individuals
who did not consent to the survey but were eligible and con-
senting with MDA were offered MDA participation only.
Treatment. Three villages were assigned to two MDA
groups. The first group (Paga and Lewomada) received annual
treatment with DEC (6 mg/kg) combined with ALB (400 mg)
and Pruda village received twice-yearly treatment with DEC/
ALB. The distribution of DEC/ALB was performed in collabo-
rationwith the health authority of the local government and the
Puskesmas. The first rounds of MDA were distributed to all
eligible residents in Paga and Pruda in March 2011 and in
Lewomada in March 2012. Annual MDA was provided every
12 months, whereas Pruda received additional treatments at
month 6 and 18 after the first treatment. Thus, Paga and
Lewomada received a total of three rounds of MDA over a
period of 24 months, whereas Pruda received five rounds.
Reexaminations were performed annually, and the last survey
was performed 36 months after the first treatment (12 months
after the last round of MDA). The last surveys were performed
in March 2014, in two study villages (Paga and Pruda), and in
March 2015 (Lewomada).
Detection of Mf by microscopy. A total of 250 μL of finger
blood was collected at night (between 8 and 11 PM) in an
ethylenediaminetetraacetic acid (EDTA)-coated tube. Sixty
microliters of blood was evenly spread in three lines onto a
clean glass slide labeled with unique barcode for each par-
ticipant, dried for 2 days, de-hemoglobinized for 3 minutes,
air-dried, fixed with methanol for 1 minute, and stained with
Giemsa (1:14) for 15 minutes. The stained slides were exam-
ined under the microscope for the presence of Mf. The result
from each slidewas entered into a cellular phone and linked to
the participant’s barcode with a barcode reader. The remaining
blood samples were centrifuged, plasma was separated for
later immunoglobulin G4 (IgG4) antibody or antigen detection,
andstoredat−20C.Plasmasampleswere transportedwith ice
packs to the laboratory of the Department of Parasitology in
Jakarta and stored at −20C until use.
Detection of antifilarial antibodies and circulating
filarial antigen.Specific antifilarial IgG4 antibodies reactive to
the recombinantB.malayi antigen BmR1were detected using
the Brugia Rapid test (BR) (Reszon SdnBhd, Bangi, Malaysia).
The test was performed using 25 μL of plasma according to the
recommendation of themanufacturer.5 CirculatingW. bancrofti
antigen was detected with the Binax Now® Filariasis Test (ICT)
(Alere, Scarborough, ME) with stored plasma according to the
protocol provided by the manufacturer. The result was read
strictly at 10 minutes after application of the sample.
Data management and analysis. All data were recorded
and synchronized in a Motorola cellular phone (XT 720;
Motorola, Chicago, IL) before being sent to the server using
the LinksSystem.7 For analysis, the data were downloaded as
Excel files from the server and transferred into SPSS version
20 (Armonk, NY) or SAS version 9.4 (Cary, NC). The data be-
fore and after treatment were regarded as independent data,
so unpaired statistical tests were used. The unadjusted Mf
prevalence and antibody and antigen prevalence in each vil-
lage before and after treatment were compared and analyzed
TABLE 1
Examined study population in the three sentinel study areas in Sikka district, province Nusa Tenggara Timur, Indonesia
Paga Lewomada Pruda Total
Males (%) Total Males (%) Total Males (%) Total Males (%) Total
Pre-mass drug administration 546 (37.8) 1,443 311 (43.1) 722 488 (47.2) 1,033 1,345 (42.1) 3,198
Year 1 392 (39.4) 994 360 (42.6) 846 475 (47.1) 1,007 1,227 (43.1) 2,847
Year 2 426 (38.2) 1,114 382 (44.5) 858 500 (47.9) 1,043 1,308 (43.4) 3,015
Year 3 358 (39.6) 905 400 (45.9) 871 437 (42.5) 1,028 1,195 (42.6) 2,804
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using a chi-square test. Changes in infection prevalence of
filarial infections were assessed by Fisher’s exact test. The
geometric mean of Mf density was calculated with data from
persons with microfilaremia. The Mf, ICT, and BR outcomes
were later analyzed using a logistic regression analysis;
neighborhood nested within village was treated as a random
effect to account for correlation among subjects within a
neighborhood (PROCGLIMMIX, SAS 9.4). In this analysis, we
assessed the treatment regimen, time, and their interaction.
The interaction termwas retained if it was significant (P<0.05),
otherwise it was removed from the model. The final model
for each outcome was also used to obtain model-adjusted
prevalence estimates. Twoof the villagesdid not haveBRdata
for years 1 and 2. Thus, only the baseline and 3-year datawere
considered in the analysis of this outcome.
RESULTS
Demographics and treatment coverage. The number of
subjects enrolled each year varied between 2,804 and 3,198
subjects (Table 1). In all villages, fewer males (between 37.8%
and 47.9%) were examined compared with females. Parame-
ters such as age distribution and bed net use were very similar
between the two treatment areas. Compliance (subjects who
reported taking antifilarial drugs during MDA) was assessed
during the follow-up surveys. This varied between 70.1% and
89.8%with thehighest reportedcomplianceobserved inPruda,
the area that received twice-yearly MDA (Table 2).
Prevalence and density of Mf. During the pre-MDA sur-
veys, it became clear that the baseline prevalence in the three
study areas (Paga, Lewomada, and Pruda) wasmore different
than expected: Whereas Paga and Lewomada had a low un-
adjusted Mf prevalence of 3.9% and 5.0%, respectively; the
Mf prevalence in Pruda was 14.2% (Table 3). In Paga, the low
prevalence was relatively evenly distributed, whereas in
Lewomada, most of the area had low prevalence, but one
sub-village (Henga) with about 300 residents had a higher
prevalence of about 10%.
Following three roundsofMDA,Mfprevalencedecreased to
zero in Paga and to 0.3% in Lewomada, whereas after five
semiannual rounds of MDA, the Mf prevalence in Pruda was
still 1.2% (Table 3). Logistic regression analysis of Mf results
showed that the overall effect for the semiannual treatment
regimen had 3.9 times higher odds (P < 0.001) of having Mf
compared with subjects receiving an annual dosage (Table 4).
This difference is likely driven by the higher overall prevalence
differences at baseline in the different villages (see the pre-
vious paragraph). Although there was not a significant
treatment × time interaction, there was an overall significant
decrease inMf over time (P<0.001), indicating that theoddsof
Mf positivity decreased by 67% each year. Furthermore,
model-adjusted prevalence estimates indicated that the
twice-yearly treatment decreased the adjusted Mf prevalence
more rapidly through time as compared with the annual
treatment regimen (Table 5).
Analysis of Mf prevalence by age group showed similar
patterns in all three study areas with low prevalence in the
younger participants and higher prevalence in older partici-
pants (Figure 2). In all areas, reduction in Mf prevalence after
MDA was also higher in younger subjects.
The Mf prevalences at baseline in males in Paga, Lew-
omada, and Pruda were 4.4% (geometric mean in positives,
172 Mf/mL), 6.4% (geometric mean 517 Mf/mL), and 18.2%
(geometric mean 284 Mf/mL), respectively. Corresponding
prevalence in females were 3.6% (geometric mean 104 Mf/
mL), 3.9% (geometric mean 160 Mf/mL), and 10.7% (geo-
metric mean 178 Mf/mL), respectively (Table 6). The gender
differences for prevalence and density weremore dramatic for
participants older than 14 years. After three or five rounds of
MDA in total, only three Mf-positive adult men but 12 Mf-
positive adult women were detected. This suggests that after
MDA, women of child-bearing age may still represent a res-
ervoir for Mf.
Brugia timori and W. bancrofti coinfections. No
W. bancrofti Mf were detected at baseline or during follow-up
surveys in Paga. Furthermore, the prevalence of circulating
W. bancrofti antigen as measured by ICT was less than 1% at
baseline. Therefore, this areawas considered to be not endemic
for W. bancrofti and not further tested by ICT. By contrast,
Lewomada and Pruda areas were both co-endemic forB. timori
and W. bancrofti. In Lewomada (at baseline), 36 Mf-positive
subjects were identified (5% of the total tested, including 13
children younger than 16 years): 33 were positive for B. timori
only with a geometric mean density of 290 Mf/mL, two individ-
uals were Mf positive for B. timori (33 Mf/mL and 867 Mf/mL,
respectively) and W. bancrofti (1,383 Mf/mL and 1,067 Mf/mL,
respectively), and one individual wasMf positive forW.bancrofti
only (67Mf/mL). All threeW. bancroftiMf-positive subjects were
also ICT positive.
Mf prevalence was highest in Pruda. Among the 146 Mf-
positive subjects (14.2%of the total tested), 106 (10.3%)were
TABLE 3
Summaryof prevalenceofMf, positive BR IgG4antibody test, and circulatingWuchereria bancrofti antigen (ICT) beforeMDAand following 1, 2, and
3 years of initiating MDA
Paga Lewomada Pruda
% Mf (CI) % BR (CI) % ICT (CI) % Mf (CI) % BR (CI) % ICT (CI) % Mf (CI) % BR (CI) % ICT (CI)
Pre-MDA 3.9 (3.0–5.0) 12.5 (10.5–14.7) Nd 5.0 (3.6–6.8) 31.7 (28.3–35.2) 6.5 (4.9–8.5) 14.2 (12.2–16.5) 28.9 (25.7–32.3) 22.9 (20.4–25.5)
Year 1 1.1 (0.6–2.0) Nd Nd 1.1 (0.6–2.0) 19.9 (17.2–22.8) 1.5 (0.8–2.5) 3.8 (2.7–5.1) Nd 9.1 (7.4–11.0)
Year 2 0.5 (0.2–1.2) Nd Nd 0.7 (0.3–1.5) 15.7 (13.4–18.3) 1.5 (0.8–2.5) 1.4 (0.9–2.4) Nd 10.2 (8.5–12.3)
Year 3 0 (0.0–0.4) 1.8 (1.1–2.9) Nd 0.3 (0.1–1.0) 4.1 (2.9–5.6) 0.8 (0.4–1.7) 1.2 (0.7–2.0) 3.6 (2.6–5.0) 7.0 (5.6–8.8)
BR = Brugia Rapid; CI = 95% confidence interval; MDA =mass drug administration; Mf = microfilariae; Nd = not determined. Paga and Lewomada received annual MDA (three rounds), whereas
Pruda received semiannual MDA (five rounds).
TABLE 2
CompliancewithMDA in the studypopulation (aged5 years and older)
in the three sentinel study areas in Sikka district
Paga Lewomada Pruda Total
N % N % N % N %
Year 1 735 73.9 683 80.7 817 81.1 2,235 78.5
Year 2 781 70.1 614 71.6 847 81.2 2,242 74.4
Year 3 731 80.8 648 74.4 922 89.8 2,301 82.1
MDA = mass drug administration. Participants were asked during the survey whether they
participated in any lymphatic filariasis MDA in the previous year.
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B. timori Mf positive and 89 (8.6%) were W. bancrofti Mf
positive. Among the W. bancrofti Mf positives, 87 (97.8%)
were also ICT positive. Based on the prevalence of single in-
fections and under the assumption of independent trans-
mission, it was calculated that prevalence of coinfections
should be about 0.09%. Interestingly, the number of Mf-
positive coinfections was 49 (4.8% of the total number of
participants tested) and much higher than expected (Table 7).
Because of this fairly even distribution of both filarial infec-
tions, we were able to assess the effect of MDA on both
species in the same study area. TheMf prevalence ofB. timori
only,W.bancroftionly, andcoinfections in this areadecreased
from 5.6%, 3.9%, and 4.8% at baseline to 1.0%, 0.2%, and
0% after five rounds of MDA, respectively (Table 7).
Prevalence of positive Brugia Rapid antibody tests. The
unadjusted prevalence of filaria-specific IgG4 antibodies as
assessed by the BR test was 12.5% at baseline in the once-
yearly treatment areas Paga and Lewomada and 41.7%
in Pruda (Table 3). At the reexamination 3 years after the first
round ofMDA, BRprevalence decreased significantly to 1.8%
and 4.1% in the annual and semiannual treatment areas, re-
spectively. Logistic regression analysis showed no significant
difference between changes in BR prevalence by treatment
area (Table 4). BR prevalence decreased by 90% over 3 years
in both areas (Table 4).
Analysis of BR antibody prevalence in the annual MDA vil-
lages by age shows that almost no children and young adults
aged 20 years and younger were positive in Paga, whereas
more children and young adults were positive in Lewomada
(Figure 3A and B). Although the Mf prevalence was highest in
Pruda, it was aB. timori/W. bancroftimixed infection area, and
the baseline BR prevalence was only 28.9% (lower than in
Lewomada). The BR prevalence decreased to 3.6% in year 3
(Table 3). As in Lewomada, few children and young adults
were BR positive in year 3. These results show that in all vil-
lages, the BR prevalence decreased significantly in all age
groups after MDA (Figure 3A–C). Thus, BR prevalence de-
creased relatively quickly in response to MDA following the
clearance of Mf.
ICT antigen test results.Wuchereria bancroftiMf-positive
individuals were only detected in Lewomada and Pruda.
Baseline ICT antigen prevalences for these areas were 6.5%
and 22.9%, respectively. After three rounds of MDA in Lew-
omada and five rounds of MDA in Pruda, ICT prevalences
decreased to 0.8% and 7.0%, respectively (Table 3). The de-
crease in antigen prevalence in Lewomadawith a low baseline
antigen prevalence was more rapid than that in Pruda where
the baseline prevalencewas high. Logistic regression analysis
of the posttreatment ICT results showed that the semiannual
treatment had higher odds of ICT positivity as comparedwith
the annual treatment group. The interaction was significant
and the slope estimates indicated that the annual treatment
group had a stronger decline through time when compared
with the semiannual treatment group (Table 4). However,
model-adjusted prevalence estimates revealed that there is a
stronger decline between baseline and 3-year in the semi-
annual treatment group (20.9% at baseline to 6% at 3 years)
as compared with the annual treatment group (1.8% at
baseline to 0.17% at 3 years) (Table 5). Analysis of results
from both Mf and ICT outcomes suggests that interpretation
of effects on the odds scalemasks themore rapid changes in
prevalence through time for the semiannual treatment group
that is evident in the unadjusted and adjusted prevalence
estimates.
Analysis of ICT antigen prevalence by age group is con-
sistent with this finding (Figure 4). It appears thatW. bancrofti
antigen is cleared faster in persons with light infections (in low
prevalence areas or in younger subjects).
TABLE 4
Logistic regression analysis of major infection parameter outcome
Outcome Variable Group Adjusted odds ratio (95% confidence interval) P-value
Microfilariae Treatment 1 Dose/year 1.0 < 0.001
2 Doses/year 3.92 (1.98, 7.78)
Visit NA 0.33 (0.28, 0.39) < 0.001
Brugia Rapid Treatment 1 Dose/year 1.0 0.31
2 Doses/year 1.49 (0.67, 3.31)
Visit NA 0.08 (0.06, 0.11) < 0.001
ICT antigen* Treatment 1 Dose/year 1.0 < 0.001
2 Doses/year 14.24 (6.2, 32.69)
Visit Slope 1 dose/year 0.45 (0.35, 0.58) < 0.001
Slope 2 doses/year 0.62 (0.56, 0.69) < 0.001
Outcome was adjusted for potential correlation among subjects within a neighborhood. Neighborhood (village) was treated as a random effect for all villages.
* The Treatment × visit interaction effect for this outcomewas significant (P = 0.016), and the odds ratios of the slopes for annual and semiannual treatment are reported to facilitate interpretation.
TABLE 5
Model predictions (adjusted prevalence) of major infection parameter outcome for annual (1 dose/year) and semiannual (2 doses/year) mass drug
administration
Treatment regimen Round
Model-adjusted prevalence and 95% confidence interval
Mf BR ICT
1 Dose/year Baseline 3.39 (2.12, 5.37) 19.8 (12.77, 29.4) 1.83 (1, 3.32)
2 Doses/year Baseline 12.09 (7.57, 18.75) 26.91 (16.45, 40.77) 20.94 (13.09, 31.78)
1 Dose/year 1 year 1.16 (0.73, 1.83) ND 0.83 (0.46, 1.47)
2 Doses/year 1 year 4.39 (2.7, 7.05) ND 14.18 (8.67, 22.34)
1 Dose/year 2 year 0.39 (0.24, 0.64) ND 0.37 (0.2, 0.71)
2 Doses/year 2 year 1.51 (0.89, 2.53) ND 9.35 (5.58, 15.25)
1 Dose/year 3 year 0.13 (0.07, 0.23) 2.04 (1.22, 3.4) 0.17 (0.08, 0.37)
2 Doses/year 3 year 0.51 (0.28, 0.92) 3.02 (1.63, 5.52) 6.04 (3.5, 10.24)
Outcome was adjusted for potential correlation among subjects within a neighborhood. Neighborhood (Village) was treated as a random effect for all villages.
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DISCUSSION
Indonesia has a 50-year history of local LF control using
village-based low-dose DEC distribution. A classic example
was the sustainable control of B. timori in a single village in
Flores Island.8,9 Unfortunately, elimination of LF was not the
goal of this intervention, efforts were restricted to relatively
small geographic areas, and the fear of adverse events, es-
pecially in areaswith brugian filariasis, hindered the expansion
of the efforts. After clinical trials indicated that DEC combined
with ALB was safe and efficacious for LF caused by
B. timori,10,11 Indonesia joined the GPELF in 2002 and
implemented the WHO recommended MDA strategy using
FIGURE 2. Microfilariae (Mf) prevalence in the study villages Paga
(A), Lewomada (B), andPruda (C) by agegroup, at baseline and follow-
up 1, 2, and 3 years following initiation of mass drug administration
(MDA). Paga and Lewomada received three rounds of MDA after the
baseline survey andat 12 and 24months,whereasPruda received five
rounds of MDA with additional rounds at 6 and 18 months. This figure































































































































































































































































































































































































































































































































































































































































































































































































340 SUPALI AND OTHERS
annual administration of this drug combination.12 In the pre-
sent study, we compared the effect of three annual rounds or
five semiannual roundsofMDAusingDECcombinedwithALB
on LF caused by B. timori and W. bancrofti in Flores Island,
Indonesia. Reported compliance rates were above 65% in all
study areas, and it appears that semiannual MDA did not
significantly increase the cumulative compliance as reported
by study participants.
Thebaseline LFprevalences in the study areaswere lower in
areas that received three rounds of annual MDA, whereas the
higher prevalence area received five rounds of semiannual
MDA. In the two areas that received annual MDA, both the
unadjusted and adjusted Mf prevalence decreased after two
rounds of MDA to below 1%. This threshold indicates in pre-
TAS that the area is eligible for TAS.13 In the area with higher
baseline prevalence (Pruda), the unadjusted prevalence still
exceeded this threshold after fivesemi-annual roundsofMDA,
suggesting that additional rounds are needed. These results
indicate that baselineMf prevalencemay be amore important
determinant for whether an area is ready for TAS than the
number of rounds or frequency of MDA alone. Many studies
haveshown that high compliance is a key factor for a successful
MDAprogram.6,14 Lowprevalence areaswith good compliance
may be eligible for TAS even after a couple of rounds, whereas
some high prevalence areasmay needmore than five rounds of
semiannual MDA despite good compliance.
At baseline, we observed higher Mf prevalence in males
comparedwith females, especially inadultsolder than15years,
and this subpopulationshouldbe specifically addressedduring
social mobilization in early stages ofMDA programs. HigherMf
prevalence inmen is often seen in LF.15 Interestingly, at the end
of theMDAprogram,most remainingMf-positive subjectswere
women older than 15 years. Therefore, it may be helpful to
specifically target adult women in eastern Indonesia in later
stages of LF elimination programs. Previous studies in eastern
Indonesia on the knowledge, attitudes, and practices con-
cerning LF have indicated that factors that influence compli-
ance changeover the courseof anLFMDAprogram, andsocial
mobilization campaigns may have to be specifically tailored to
changing target groups.16
Differences in baseline prevalence make it difficult to com-
pare the impact of annual and semiannual MDA in the present
study. Computer modeling studies using assumptions for
W. bancrofti infections from Ghana and India predicted that
twice-yearly MDA would reduce the duration of MDA pro-
grams in half and reduce the overall program costs.6 Although
this may be true in some settings, our data from Flores are not
consistent with these predictions. It appears that annual MDA
with DEC and ALB can be highly effective in areas with low to
moderate Mf prevalence, and high compliance may be more
important than the frequency of MDA rounds.
Whereas the Paga area was endemic forB. timori alone, the
other two areas were co-endemic for B. timori and
W. bancrofti. The prevalence of circulating W. bancrofti anti-
genemia in Lewomada was 6.5%, but only threeW. bancrofti
Mf-positive individuals were detected at baseline. Therefore,
we focused our comparison of the effects of MDA on the two
infections on the data from Pruda, which had high baseline
prevalences for both infections. Our results showed clearly
that at baseline, coinfections with B. timori and W. bancrofti
were more common than expected. Both filarial species are
transmitted by anopheline mosquitos, but by different vector
species.OnAlor Island, for example,B. timori is transmittedby
Anopheles barbirostris, whereasW.bancrofti is transmitted by
Anopheles subpictus.15 The high prevalence of coinfection
suggests that the same people may be heavily exposed to
bites from both vector mosquito species. Furthermore, it ap-
pears that both filarial species responded well to MDA; be-
cause the prevalence of B. timori was higher than that of
W. bancrofti at baseline, the residual prevalence of B. timori
was also slightly higher after five rounds of MDA.
In the absence of a reliable antigen test for brugian filariasis,
the BR test has been recommended for mapping and moni-
toring and evaluation of LF elimination programs in Brugia-
endemic areas.13 Previous studies have shown that this
antibody test is sensitive for both B. malayi and B. timori in-
fections17 and that BR prevalences decrease followingMDA.5
However, the present study demonstrates that BR preva-
lences decreased rapidly after MDA in three different areas: in
the low prevalence area (Paga), the prevalence decreased
over 36months to 14.4%of the baseline prevalence and in the
higher prevalence areas, it decreased to 12.9% (Lewomada)
and 12.5% (Pruda) of the baseline values. Furthermore, the
analysis by age group showed that the decline was seen in all
age groups and was not limited to children and young adults.
The posttreatment decrease in BR antibody prevalence is
faster than that reported from W. bancrofti infections for an-
tibodies reactive to the filarial antigen Bm14.18 This may be
related to a special property of recombinant BmR1 antigen
used in the test and to the diagnostic platform. In previous
studies, antibodies reactive with Bm14 antigenwere detected
by ELISA, whereas the point-of-care BR test used in the pre-
sent study detects antibodies reactive with BmR1 antigen by
paper immunochromatography. IgG4 antibodies reactive with
the BmR1 antigen may decrease quickly below the detection
threshold of BR, but this does not necessarily mean that
antifilarial antibodies reactive with the BmR1 antigen have
been totally cleared.
The areas Lewomada and Pruda were co-endemic for
W. bancrofti, and circulating antigen prevalences were
assessedby ICT. ICTprevalencesdecreasedover 36months to
12.3% and 30.6%of the baseline in these two treatment areas,
TABLE 7
The change of Mf prevalence and density over time in single and in mixed infection of Brugia timori andWuchereria bancrofti in Pruda, the twice-
yearly treated village
N
B. timori W. bancrofti B. timori + W. bancrofti
n Mf+ (%, CI) Geomean (Mf/mL) n Mf+ (%, CI) Geomean (Mf/mL) n Mf+ (%, CI) Geomean B. timori (Mf/mL) Geomean W. bancrofti (Mf/mL)
Pre-mass drug
administration
1,027 57 5.6 (4.3–7.1) 114 (77–167) 40 3.9 (2.9–5.3) 148 (97–227) 49 4.8 (3.6–6.2) 401 (251 –641 ) 163 (106–249)
Year 1 982 10 1.0 (0.5–1.9) 200 (40–1,008) 23 2.3 (1.6–3.5) 105 (64–170) 4 0.4 (0.2–1.0) 297 (83–1,070) 157 (9–2,645)
Year 2 1,042 5 0.5 (0.2–1.1) 120 (23–632) 6 0.6 (0.3–1.2) 102 (23–453) 3 0.3 (0.1–0.8) 82 (7–1,045) 126 (18–871)
Year 3 1,027 10 1.0 (0.5–1.8) 54 (25–119) 2 0.2 (0.05–0.7) 24 (0.3–1,927) 0 0 (0.0–0.4) Nd Nd
CI = confidence interval; Mf = microfilariae.
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respectively. The more rapid decrease in Lewomada may be
related to the relatively low prevalence and intensity of infection
in that treatment area. Decreases in ICT prevalence following
MDA have been reported many times before, and it is well
known that circulating antigen levels decrease a few months
after successful treatment.19,20 The finding that BR prevalence
decreased more rapidly than ICT in Pruda (co-endemic for
B. timori andW. bancrofti) is an interesting new finding.
In conclusion, our study did not detect an obvious advan-
tage of twice-yearly MDA in areas that were co-endemic for
B. timori and W. bancrofti. However, differences in baseline
infection prevalence in this study may have obscured the
potential superiority of semiannual MDA. The study showed
that three rounds of once-yearly MDA with fairly high com-
pliance reducedMfprevalence tobelow1% in low-endemicity
areas. High compliance with annual MDAmay be sufficient to
eliminate LF in most settings, and compliance is probably
more important than the frequency of MDA. Our results also
suggest that the BR antibody test is a good marker for suc-
cessful MDA in areas with brugian filariasis.
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FIGURE 4. Prevalence of positive ICT antigen tests for Wuchereria
bancrofti in the study villages Lewomada (A) and Pruda (B) by age
group, at baseline and follow-up1, 2, and 3 years following initiation of
mass drug administration (MDA). Lewomada received three rounds of
MDA after the baseline survey and at 12 and 24 months, whereas
Pruda received five rounds of MDA with additional rounds at 6 and 18
months. This figure appears in color at www.ajtmh.org.
FIGURE 3. Prevalence of positive Brugia Rapid (BR) antibody tests
in the study villages Paga (A), Lewomada (B), and Pruda (C) by age
group at baseline and 3 years following initiation of mass drug ad-
ministration (MDA). In addition, in Lewomada Brugia Rapid tests were
also performed in year 1 and 2 after the start of MDA. Paga and
Lewomada received three rounds of MDA after the baseline survey
and at 12 and 24months, whereas Pruda received five rounds ofMDA
with additional rounds at 6 and 18months. This figure appears in color
at www.ajtmh.org.
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